Drugs / CAR19BCMA-T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06986434 | Apr 2026 → May 2027 expected | plasma cell neoplasm | Affiliated Hospital to Academy of Military Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR19BCMA-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06986434 ↗ |
| Known as | CD19BCMA-CAR-T cells | “CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells.” NCT06986434 ↗ |